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 ABSTRACT
Amyloidoses are a group of heterogeneous diseases classified according to the nature of their causative 
amyloid proteins. Commonly, paraffin-embedded tissue is used for the typing of amyloid by immunohisto-
chemistry. DNA analysis should always be considered if hereditary amyloidosis is suspected. Since the kidneys 
are one of the organs that are most commonly involved in amyloid deposition in systemic amyloidoses, we 
screened 102 consecutive cases with biopsy-proven amyloid disease by immunohistochemistry. DNA analysis 
was performed to confirm a diagnosis of hereditary amyloidosis. Demographic characteristics, underlying 
disease and clinical data at the time of renal biopsy were obtained by retrospective review of medical records.
The amyloidosis type according to immunohistochemical amyloid protein identification was AA in 60 
(58.8%) patients, AL in 21 (20.6%), AFib in four (3.9%), ATTR in two (2.0%), AApoAI in one (1.0%), ALys in 
one (1.0%) and combined AL and AA in one (1.0%). The type of protein could not be classified in 12 (11.7%) 
patients: eight (7.8%) because of negative immunohistochemistry and four (3.9%) due to the lack of adequate 
tissue. DNA analysis confirmed AFib and ATTR cases by the identification of the point mutations FGA 
p.Glu545Val and TTR p.Met51Val, respectively. Mean age at diagnosis was 53.3 years (49.4 for AA, 63.0 for 
AL and 53.9 for AFib). Chronic infections were the most frequent disorder associated with AA amyloidosis, 
mainly tuberculosis, and only one patient had familial AA associated with Muckle-Wells syndrome. Nephrotic 
syndrome was the most frequent clinical manifestation, independently of the amyloid type.
In our series, AA amyloidosis is still the most frequent type of systemic amyloidoses. Six patients had 
unequivocal hereditary amyloidosis. Immunohistochemistry did not establish the precursor protein in almost 
8% of patients; however, an improvement could be obtained using a wider panel of amyloid antibodies.
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 INTRODUCTION
Amyloidoses comprise a heterogeneous group of 
diseases that have in common tissue deposits of 
extracellular fibrillary proteins of similar structure 
but different chemical composition1-3. Although they 
have been known since the time of Virchow, in the 
19th century4,5, until recently amyloidoses were con-
sidered a medical curiosity with only academic inter-
est rather than clinically relevant diseases. However, 
recent advances in the treatment of systemic amy-
loidoses have changed this position and, hence, the 
importance of an early and correct diagnosis of the 
type of amyloid has gained relevance6-11. The sample 
to be analysed must be of reasonable quality and 
quantity. Currently, amyloid deposits are identified 
on the basis of their apple-green birefringence under 
polarized light microscopy in Congo red stained his-
tological preparations, the gold standard for amyloid 
detection, and the presence of rigid, non-branching 
fibrils 7.5 to 10 nm in diameter, on electron 
microscopy12. Immunohistochemical identification of 
the chemical type of amyloid is still the first step in 
classifying amyloid13. However, it must be performed 
and interpreted with caution and inconclusive results 
must be further evaluated using more sophisticated 
methods available in referral centres9,14. Additional 
genetic testing should be performed if a hereditary 
form is suspected after amyloid protein typing9,15. 
In cases in which DNA sequencing detects a mutant 
amyloid precursor, protein analysis is the definitive 
evidence9. To date, more than 25 different proteins 
have been recognized as causative agents of amyloid 
diseases16. The two most common types of systemic 
amyloidoses, commonly associated with renal 
involvement, are immunoglobulin-derived amyloido-
sis, secondary to plasma cell dyscrasia, and serum 
amyloid A derived amyloidosis (AA), which is typically 
associated with chronic inflammation. The deposits 
in immunoglobulin-derived amyloidosis in the vast 
majority of patients are composed of fragments of 
monoclonal immunoglobulin light chains (AL), but 
 RESUMO
As amiloidoses são um grupo heterogéneo de doenças classificadas de acordo com a composição das 
suas proteínas amiloidogénicas. Frequentemente, os tecidos preservados em parafina são usados para 
identificação imunohistoquímica. A análise de ADN deve ser sempre considerada se houver suspeita de 
amiloidose hereditária. Dado que os rins são um dos órgãos mais frequentemente envolvidos nas amiloi-
doses sistémicas, procedemos à classificação imunohistoquímica de 102 casos consecutivos de doença 
amiloide confirmada por biópsia renal. A análise de ADN foi realizada para confirmar o diagnóstico de 
amiloidose hereditária. As características demográficas, doença subjacente e dados clínicos à data da biópsia 
foram obtidos pela revisão retrospetiva dos registos médicos.
O tipo de amiloidose obtido por identificação imunohistoquímica foi AA em 60 (58,8%) doentes, AL em 
21 (20,6%), AFib em quatro (3,9%), ATTR em dois (2,0%), AApoAI em um (2,0%), ALys em um (2,0%), e 
em um (2,0%) coexistiam os tipos AL e AA. Em 12 (11,7%) não foi identificado o tipo de amiloide: oito 
(7,8%) por imunohistoquímica negativa e quatro (3,9%) devido a amostra insuficiente. A análise de ADN 
confirmou os casos AFib e ATTR pela identificação das mutações pontuais FGA p.Glu545Val e TTR p.Met51Val, 
respetivamente. A média de idade à data do diagnóstico foi 53,3 anos (49,4 para AA, 63,0 para AL e 53,9 
para AFib). As infeções crónicas foram a principal causa de amiloidose AA, sobretudo a tuberculose, e foi 
apenas identificada uma AA familiar associada a síndrome de Muckle-Wells. A síndrome nefrótica foi a 
manifestação clínica mais frequente, independentemente do tipo de amiloide.
Na nossa série, a amiloidose AA continua a ser a amiloidose sistémica mais frequente. Seis doentes tiveram 
amiloidose hereditária inequívoca. A imunohistoquímica não identificou a proteína precursora em quase 8% 
dos doentes; contudo, a utilização de um painel de anticorpos mais alargado poderá melhorar o diagnóstico.
Palavras-chave: Amiloidose; diagnóstico; hereditário; imunohistoquímica; rim.
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Renal amyloidosis: classification of 102 consecutive cases
seldom develop from fragments of heavy chains 
(AH)17-19. Other rare forms of amyloidoses with renal 
involvement are those derived from transthyretin 
(ATTR)20, gelsolin (AGel)21, apolipoprotein A-I 
(AApoAI)22, fibrinogen A -chain (AFib)23, lysozyme 
(ALys)24, apolipoprotein A-II (AApoAII)25, apolipo-
protein A-IV (AApoAIV)26, and from the leukocyte 
chemotactic factor 2 (ALect2)27. This newly described 
form of amyloidosis is mainly a renal disease from 
a clinical perspective, although not enough is known 
yet about ALect2 to draw conclusions about the 
distribution of amyloid deposits27. A precise epide-
miology of amyloidoses is difficult to define as the 
disease is often undiagnosed or misdiagnosed. Selec-
tion bias of data from tertiary centres becomes poten-
tially unrepresentative1,15. In Portugal, ATTR is the 
most frequent form of hereditary systemic amyloi-
dosis. Since the identification of the disease as a 
new entity, in 1939, Hospital Santo António is the 
reference centre for this disease. Apart from ATTR, 
there is not a vast knowledge about the type of 
systemic amyloidoses in Portugal. The aims of this 
study were: (1) to classify by immunohistochemistry 
the type of amyloidosis of a northern Portuguese 
series evaluated outside the referral centre; (2) to 
identify amyloidogenic variants in the hereditary 
forms; (3) to determine underlying disorder, clinical 
and laboratory findings at the time of kidney 
biopsy.
 SUBJECTS AND METHODS
The department of Nephrology of the Centro Hos-
pitalar São João (CHSJ), in collaboration with the 
department of Renal Pathology of CHSJ, has a registry 
of native kidney biopsies with amyloid nephropathy 
diagnosed since 1978. The absence of amyloid type 
classification led the Nephrology department of CHSJ 
to start a systematic classification of all cases of 
amyloid nephropathy by immunohistochemistry. We 
conducted a retrospective review of 102 consecutive 
native kidney biopsies, from patients of northern 
Portugal, performed between May 1978 and Septem-
ber 2013. Five of those patients had one or two 
additional kidney biopsies. For those patients, only 
the first diagnostic biopsy was analysed. DNA studies 
were performed for confirmation of the amyloid type 
in suspected hereditary amyloidosis based on the 
protein identified in the deposits.
The study was reviewed and approved by the 
Health Ethics Commission of CHSJ.
 Histology and Immunohistochemistry
All the immunohistochemistry slides were reviewed 
by a pathologist and a nephrologist with expertise 
in amyloid nephropathy. Congo red staining was 
performed on 6 μm thick formalin-fixed paraffin-
embedded sections, and the presence of amyloid 
was analysed microscopically under polarized light. 
Immunohistochemical staining was performed on 2 
μm thick formalin-fixed paraffin-embedded sections 
of the amyloid containing biopsies, using standard 
methods and a ready-to-use rabbit/mouse, peroxi-
dase/diaminobenzidine (DAB) detection system (Dako 
Real Envision). The monoclonal antibodies used were 
directed against serum amiloid A (Dako), apolipo-
protein A-II (Abcam) and transthyretin [provided by 
one of the authors (PPC)]28; polyclonal antibodies 
were used for κ-light chain, λ-light chain, fibrinogen 
A -chain, transthyretin, apolipoprotein A-I and lyso-
zyme (all from Dako). For light chains and fibrinogen 
detection, sections were treated with 10 μg/mL pro-
teinase K for 10 minutes at 37°C and 10 minutes at 
room temperature. Blocking was done with 5% 
bovine serum albumin/phosphate-buffered saline 
(BSA/PBS). The sections were incubated with the 
respective antibody for 2 hours at room temperature, 
diluted in 1% BSA/PBS, as follows: monoclonal anti-
TTR was used directly; polyclonal anti-TTR 1:500; 
anti-SAA 1:100; anti-kappa 1:1000; anti-lambda 
1:2000; anti-Fib 1:800; Anti-Lys 1:300; anti-Apo A-I 
1:400; anti-Apo A-II 1:600.
 DNA Sequence Analysis
We searched for DNA mutations in the genes coding 
for the proteins identified in the immunohistochemistry. 
DNA was isolated from peripheral blood leukocytes 
using the “Genomic DNA Purification Kit” (PureGene, 
Gentra Systems). The coding regions of the genes 
encoding transthyretin (exon 2), fibrinogen A -chain 
(exon 5), apolipoprotein A-I (exons 1 to 4), apolipopro-
tein A-II (exon 4), and lysozyme (exon 2) were amplified 
by polymerase-chain-reaction (PCR) using the primer 
pairs listed on Table I. PCR products were analysed by 
agarose gel electrophoresis, purified according to “High 
Pure PCR Purification Kit” (Roche) and sequenced with 
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the “BigDye Terminator v3.1 Cycle Sequencing Kit” 
(Applied Biosystems). Sequence results were analysed 
with ChromasPro and Ridom TraceEdit.
 Patients and Data Collection
A total of 102 consecutive patients with different 
types of amyloidoses were included. For each patient, 
data was obtained from retrospective review of medi-
cal records: date of birth, sex, underlying diseases, 
main clinical manifestation of renal involvement at 
the date of kidney biopsy.
The following clinical definitions were used: (1) 
nephrotic syndrome: nephrotic-range proteinuria (≥
3.0 g/d) with hypoalbuminemia (< 3.5 g/d) and periph-
eral oedema; (2) glomerular filtration rate estimation 
(GFRe) using 2009 CKD-EPI creatinine equation29; 
(3) hypertension (HTN) was classified according to 
2013 ESC/ESH guidelines30.
 Statistics
All statistical analyses were performed in IBM SPSS 
version 20.0 for Windows. Descriptive statistics of 
nominal variables consisted on frequencies. Kol-
mogorov-Smirnov test was used to assess the nor-
mality of cardinal variables, and for this test the null 
hypothesis was rejected when p < 0.05. Despite the 
small size of some subsamples, means and standard 
deviations were used, as all the described cardinal 
variables presented normal distribution, and the use 
of medians and percentiles would not be more appro-
priate in such small groups.
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Table I
Primer sequences used for TTR, FGA, APOA1, APOA2 and LYZ genes.
Gene Exon Forward Primer Reverse Primer
TTR 2 5’-CTTGTTTCGCTCCAGATTTC-3’ 5’-GGGCAAACGGGAAGATAA-3’
FGA 5 5’-TGATGAAGCTGCCTTCTTCGA-3’ 5’-CTCATCTGCCATTTTATAGCT-3’
APOA1 1-3 5’-GCCCCCACTGAACCCTTGA-3’ 5’-TAGGTGAGGACTCGGCCAGTCTGG-3’
APOA1 4 5’-CTGATAGGCTGGGGCGCTG-3’ 5’-AAGCTGCTTCCCACTTTGG-3’
APOA2 4 5’-CTAATCCCCTCACCTA-3’ 5’-GGAAGACAATGGTCTG-3’
LYZ 2 5’-AGTCACTTAGTGTTGCTGTTT-3’ 5’-ACCAGATTGGTCAAATATTAG-3’ 
Table II
Data at kidney biopsy according to amyloid type.
Amyloid type
Patients
n (%)
Males
(%)
Age at diagnosis (yr)
Mean (SD)
HTN
(%)
NS
(%)
GFRe
(mL/min/1.73m2)
Mean (SD)
AA 60 (58.8) 51.7 49.4 (16.3) 35.0 81.7 62.5 (43.9)
AL (λ or κ)
  ALλ
  ALκ
21 (20.6)
14 (13.7)
7 (6.9)
42.9
42.9
42.9
63.0 (8.1)
65.2 (8.0)
58.8 (6.9)
38.1
42.9
28.6
76.2
85.7
57.1
51.7 (34.6)
50.8 (31.6)
53.4 (42.7)
AFib 4 (3.9) 50.0 53.9 (13.0) 100 75.0 29.4 (22.8)
ATTR 2 (2.0) 0.0 40.3 (17.9) 50.0 100 77.3 (78.9)
Combined AL and AA 1 (1.0) 100 73.6 (-) 100 100 6.7 (-)
ALys 1 (1.0) 0.0 68.1 (-) 100 100 32.9 (-)
AApoAI 1 (1.0) 100 65.7 (-) 100 100 100.2 (-)
Unclassified
  Negative IHQ
  Insufficient tissue
12 (11.7)
8 (7.8)
4 (3.9)
58.3
62.5
50.0
53.5 (13.4)
53.1 (14.9)
54.2 (11.9)
50.0
62.5
25.0
83.3
75.0
100
53.6 (38.8)
45.2 (35.2)
70.4 (45.6)
Total 102 (100) 50.0 53.3 (15.3) 41.2 81.4 57.8 (41.4)
Abbreviations: Yr, years; HTN, hypertension; NS, nephrotic syndrome; GFRe, glomerular filtration rate estimation according to CKD-EPI equation; AA, serum amyloid A amyloidosis; 
AL, immunoglobulin light chain amyloidosis; ALλ, lambda light chain amyloidosis; ALκ, kappa light chain amyloidosis; AFib, fibrinogen A -chain amyloidosis; ATTR, transthyretin 
amyloidosis; ALys, lysozyme amyloidosis; AApoAI, apolipoprotein A-I amyloidosis; IHQ, immunohistochemistry.
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 RESULTS
Clinical and laboratory characteristics of the study 
patients, both overall and according to amyloid type 
are listed in Table II.
 Amyloid Type Identification
According to immunohistochemical identification, 
the most prevalent type of amyloidosis was AA, 
corresponding to more than half of the patients 
(58.8%, n = 60), followed by AL in about one fifth 
(20.6%, n = 21). The ratio AA/AL was 2.9 to 1. The 
subtype of light chain in AL amyloidosis was λ in 
two thirds of patients. Two different types of amyloid 
deposits – light chain λ and serum amyloid A – were 
present in one patient. Immunostaining disclosed a 
predominant pattern for light chain λ deposition 
and small patchy deposits for serum amyloid A at 
different sites. AFib was the most frequent type of 
hereditary amyloidosis contributing to 3.9% (n = 4) 
of the cases. ATTR was identified in two (2.0%) 
patients, AApoAI in one (1.0%), and ALys in one 
(1.0%). The type of amyloidosis remained unclassi-
fied in 12 (11.7%) patients, mostly due to negative 
immunohistochemistry.
 Hereditary Forms and their Amyloidogenic Variants
Molecular diagnosis of hereditary forms disclosed 
the point mutations FGA p.Glu545Val in all AFib 
cases and TTR p.Met51Val in the two cases of ATTR. 
Sudden death of the ALys positive patient did not 
allow genetic study. In the AApoAI case pathogenic 
changes were not detected in the encoding region 
(exons 2 to 4) and exon-intron respective transitions 
of the APOA1 gene.
 Underlying Disease
In our series, systemic AA amyloidosis patients 
showed mainly chronic infectious complications of 
pulmonary tuberculosis (Table III). A familial AA asso-
ciated to Muckle-Wells syndrome was unequivocal in 
one patient. AL amyloidosis was related to monoclonal 
gammopathy of undetermined significance (MGUS) 
in 10 (47.6%) and multiple myeloma in eight (38.1%) 
patients, whereas the diagnosis was unknown in three 
(14.3%). The combined AL and AA amyloidosis patient 
had multiple myeloma light chain lambda and a previ-
ous history of syphilis. One of the four patients with 
AFib and the AApoAI patient also had MGUS. The 
ALys patient had rheumatoid arthritis.
 Clinical Findings at Kidney Biopsy
The clinical features at kidney biopsy are listed 
in Table II. The 102 patients included 51 (50.0%) 
females and 51 (50.0%) males. The mean age at 
time of kidney biopsy for the entire group was 53.3 
± 14.9 years. AA patients were younger and had a 
better renal function than AL and AFib. CKD-EPI esti-
mated glomerular filtration rate was 62.5 ± 43.9 mL/
min./1.73m2 for AA, 51.7 ± 34.6 mL/min./1.73m2 for 
AL and 29.4 ± 22.8 mL/min./1.73m2 for AFib patients. 
Renal amyloidosis: classification of 102 consecutive cases
Table III
Underlying disorders in 60 patients with AA amyloidosis.
Diseases n (%)
Chronic infections
Pulmonary tuberculosis
Bronchiectasis
Chronic cutaneous ulcers
Xanthogranulomatous pyelonephritis
Whipple’s disease
25 (41.7)
13
7
3
1
1 
Inflammatory arthritis
Rheumatoid arthritis
Juvenile rheumatoid arthritis
Ankylosing spondylitis
Psoriatic arthritis
Systemic lupus erythematosus
19 (31.7)
10
4
2
2
1
Inflammatory bowel diseases
Crohn’s disease
4 (6.6)
4
Neoplastic diseases
Non-Hodgkin’s lymphoma
Colon adenocarcinoma 
2 (3.3)
1
1
Acquired immunodeficiencies
HIV/AIDS
1 (1.7)
1
Hereditary diseases
Muckle-Wells syndrome
Weber-Christian disease associated with 1-antitrysin 
deficiency
2 (3.3)
1
1
Systemic vasculitides
Polymyalgia rheumatic
1 (1.7)
1 
Conditions predisposing to chronic infections
Cystic fibrosis
Dystrophic epidermolysis bullosa
Injected-drug use
3 (5.0)
1
1
1
Undetermined disease 3 (5.0)
Total 60 (100) 
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Nephrotic syndrome was the first sign of renal 
involvement in 83 (81.4%) patients with a similar 
frequency for all types of amyloidosis. The presence 
of hypertension was associated with AFib (100% for 
AFib, 38.1% for AL and 35% for AA).
The mean age of the patients at diagnosis of the 
underlying disorder was 36 ± 20 years for AA (data 
available for 53 patients) and 63 ± 9 years for AL 
(data available for 18 patients). The mean duration 
between the onset of the underlying disorder and 
the diagnosis of AA amyloidosis (data available for 
53 patients) was 13.9 ± 12.3 years and for AL amy-
loidosis (data available for 18 patients) was 1.4 ±
1.5 years.
 DISCUSSION
Here, we report the immunohistochemical classi-
fication, molecular diagnosis and clinical characteriza-
tion of 102 northern Portuguese patients with kidney 
biopsy -proven amyloid disease, evaluated outside 
the referral centre for hereditary amyloidosis.
Diagnosis for amyloid diseases needs histological 
confirmation31. Immunohistochemistry is still the most 
frequent technique used in the identification of the 
amyloid fibril protein. However, it has limitations, 
mainly related with the low sensitivity of the technique, 
spectrum of amyloid antibody panel, low quality of 
the analysed tissue and observer experience15,32-35. 
These limitations are particularly evident in the cases 
of AL and hereditary amyloidosis. Twelve (11.7%) of 
our cases were unclassified, four (3.9%) due to the 
lack of adequate tissue and eight (7.8%) because of 
negative immunohistochemistry. Whenever this occurs, 
investigation should continue using a wider antibody 
panel or emerging techniques, such as proteomics, 
that are currently performed only in highly specialized 
laboratories14,36-37, which may contribute to amyloid 
typing in more than 97% of renal amyloidosis cases38. 
AA amyloidosis was the most frequent form of systemic 
amyloidosis in our series, similarly to what was report-
ed in the largest series of renal amyloidosis in kidney 
biopsies described by Panizo39. On the other hand, 
Pinney and colleagues reported an epidemiological 
study about systemic amyloidosis in England and 
concluded that systemic AL amyloidosis was the most 
common type with an estimated minimum incidence 
of 0.3/100 000 population40. Besides the long period 
of our study, the prevalence of AA amyloidosis 
remained stable from 1978 to 2013 (Fig.1), although 
with recent advances in the treatment of chronic infec-
tious diseases and autoimmune inflammatory pro-
cesses a decline in the incidence of AA form would 
be expected39. Nevertheless, our findings agree with 
results of other series: a recent single-centre study 
detailing 20 years’ Florentine experience of AA amy-
loidosis showed that rheumatoid arthritis contributed 
to 45% of cases and 67% of patients had some form 
of renal involvement41. But, among us, chronic infec-
tious disorders are still the most frequent cause of 
AA amyloidosis, mainly pulmonary tuberculosis, which 
is according to the fact that Portugal still has one of 
the highest tuberculosis incidence rates in European 
Union countries42. One of our AA patients had a 
Muckle-Wells syndrome, which is a familial auto-
inflammatory disease, diagnosed when she was 16 
years old. Auto-inflammatory diseases are now the 
most common cause of AA amyloidosis in children, 
and paediatric nephrologists should be aware that 
renal amyloidosis is potentially preventable in these 
conditions43. Clinically significant renal diseases may 
also arise in young adults with cystic fibrosis44. Our 
patient had cystic fibrosis since age 5 and AA amy-
loidosis was diagnosed at 21 years old. Early diagnosis 
and rapid control of the underlying inflammatory or 
infectious disease are of the utmost importance to 
prevent irreversible organ damage45. Our mean dura-
tion between the onset of the underlying disease and 
the diagnosis of AA amyloidosis presented a wide 
range, nonetheless this was a retrospective observa-
tional analysis. During such a long period of time, 
patient monitoring combined with adequate therapy 
of underlying disease and periodic search for subclini-
cal amyloid deposits on abdominal fat aspiration, 
might help early diagnosis and alter the prognosis of 
the disease45. AA amyloidosis, in our series, affected 
younger individuals, which may be related to early 
beginning of most of the underlying conditions, mainly 
infectious and inflammatory diseases, and therapeutic 
failures at suppressing inflammation. However, genetic 
factors may also be involved on this namely SAA 
genotype46. A lesser degree of renal dysfunction in 
our patients may be related to an early diagnosis 
through repeated measurements of microalbuminuria 
and serum creatinine.
AL amyloidosis was our second most frequent 
form of systemic amyloidosis and these patients 
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were older than AA patients. These results should 
be interpreted cautiously since in older and unstable 
patients with monoclonal plasma cell disorders we 
may use less invasive diagnostic tests, such as 
abdominal fat aspiration or minor salivary gland 
biopsy for amyloid diagnosis as a way to minimize 
complications related to kidney biopsies.
Unequivocal hereditary amyloidosis contributed 
to 5.9% of our cases (3.9% AFib and 2.0% ATTR). 
DNA analysis is mandatory to confirm the diagnosis 
but it should always be complementary to other 
diagnostic techniques that allow unequivocal iden-
tification of amyloid protein9. Genetic defects may be 
associated with amyloidosis either as a mutation in 
non-amyloid protein, as is the case of familial AA 
patients, where an inborn error of inflammatory response 
in the innate immune system plays a permissive role 
in the development of amyloid47, or as a mutation 
involving amyloid protein itself, as is the case of 
AFib23, ATTR48, ALys24 and AApoAI22 patients. AFib 
is the most common type of hereditary amyloidosis 
in Europe49. Our four AFib patients were from the 
same region and had the same amyloidogenic muta-
tion, so haplotyping studies are necessary to con-
clude if they belong to the same family. Worst renal 
function at presentation in this small group may not 
be informative because of late diagnosis, in the 
absence of family history, due to variations in disease 
penetrance and progression. High prevalence of 
hypertension among AFib patients may be secondary 
to chronic kidney disease, but direct amyloid deposi-
tion in vascular walls may also be involved49. ATTR 
amyloidosis was identified only in two cases, what 
was expected since this study was performed outside 
the referral centre for the disease in northern Por-
tugal. For this reason, our results have no correlation 
with ATTR prevalence in our country. One of the 
patients performed kidney biopsy outside the referral 
centre because she had nephrotic syndrome and at 
the time of biopsy she denied knowing ATTR family 
history. The other patient was considered TTR
p.Met51Val asymptomatic carrier that presented with 
nephrotic syndrome and haematuria. Kidney biopsy 
Renal amyloidosis: classification of 102 consecutive cases
Figure 1
Distribution of amyloidosis type, according to immunohistochemical identification, by year of diagnosis, from 1978 to 2013. All the patients were 
evaluated at department of Nephrology from Centro Hospitalar de São João. Combined AL and AA amyloidosis is represented by AL (+AA). Unclassified 
cases are not presented.
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disclosed IgA nephropathy and medullary amyloid 
deposition. ALys and AApoAI amyloidosis were diag-
nosed by immunohistochemistry, without molecular 
confirmation, so further studies are necessary to 
confirm amyloidosis type in both cases.
Said and colleagues38 reported the origin and 
clinicopathologic correlations of 474 recent cases of 
renal amyloidosis, based on immunohistochemistry 
and laser microdissection/mass spectrometry. They 
found immunoglobulin (Ig) amyloidosis in 85.9%; 
AA in 7%; leukocyte chemotactic factor 2 (LECT2) 
amyloidosis in 2.7%; AFib in 1.3%; ApoAI, ApoAII or 
ApoAIV amyloidosis in 0.6%; combined AA /Ig heavy 
and light chain amyloidosis in 0.2%, and amyloidosis 
was unclassified in 2.3% patients38. When we com-
pare our results with those, our first conclusion is 
that we need to raise our spectrum of amyloid anti-
bodies with the inclusion of anti-LECT2, anti-Apo 
A-IV and anti-Ig heavy chain as a way to reduce 
unclassified cases.
Improvements to understanding the pathogenesis 
of systemic amyloidosis, coupled with enhancements 
on diagnostic techniques, have led to the identifica-
tion of therapeutic strategies that have already result-
ed in better outcomes for patients50, so we should 
perform routine precise identification of the amyloid 
fibril protein on tissues containing amyloid deposits. 
Our results may prove helpful for clinicians in charge 
of patients with amyloidosis regarding the decision 
for a more definitive diagnosis of the disease.
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